Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Torsten Kucharzik, Pierre Ellul, Thomas Greuter, et al.
Journal of Crohn s and Colitis (2021) Vol. 15, Iss. 6, pp. 879-913
Open Access | Times Cited: 308

Showing 1-25 of 308 citing articles:

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Tim Raine, Stefanos Bonovas, Johan Burisch, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 1, pp. 2-17
Closed Access | Times Cited: 633
Versatile carbon dots with superoxide dismutase-like nanozyme activity and red fluorescence for inflammatory bowel disease therapeutics
Yana Ma, Jingjie Zhao, Liangliang Cheng, et al.
Carbon (2023) Vol. 204, pp. 526-537
Closed Access | Times Cited: 71
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Paulina Núñez, Rodrigo Quera, Andrés Yarur
Drugs (2023) Vol. 83, Iss. 4, pp. 299-314
Open Access | Times Cited: 48
May ChatGPT be a tool producing medical information for common inflammatory bowel disease patients’ questions? An evidence-controlled analysis
Antonietta Gerarda Gravina, Raffaele Pellegrino, Marina Cipullo, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 1, pp. 17-33
Open Access | Times Cited: 27
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 4
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
Francesca Ferretti, Rosanna Cannatelli, Maria Camilla Monico, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2302-2302
Open Access | Times Cited: 65
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro‐de Acosta, Irina Blumenstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 50
Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease
Shahida Din, Christian P. Selinger, Christopher J. Black, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 6, pp. 666-675
Open Access | Times Cited: 44
Pediatric Inflammatory Bowel Disease
Marleen Bouhuys, Willem S. Lexmond, Patrick F. van Rheenen
PEDIATRICS (2022) Vol. 151, Iss. 1
Open Access | Times Cited: 43
Necrosulfonamide ameliorates intestinal inflammation via inhibiting GSDMD-medicated pyroptosis and MLKL-mediated necroptosis
Wenchang Yang, Kaixiong Tao, Yaxin Wang, et al.
Biochemical Pharmacology (2022) Vol. 206, pp. 115338-115338
Closed Access | Times Cited: 39
Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology
Piotr Eder, Michał Łodyga, Magdalena Gawron-Kiszka, et al.
Gastroenterology Review (2023) Vol. 18, Iss. 1, pp. 1-42
Open Access | Times Cited: 30
JAK inhibitors for inflammatory bowel disease: recent advances
Sailish Honap, Alexandra Agorogianni, Michael Colwill, et al.
Frontline Gastroenterology (2023) Vol. 15, Iss. 1, pp. 59-69
Open Access | Times Cited: 30
Clostridioides difficile aggravates dextran sulfate solution (DSS)-induced colitis by shaping the gut microbiota and promoting neutrophil recruitment
Danfeng Dong, Tongxuan Su, Wei Chen, et al.
Gut Microbes (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 26
Clinical guidelines. Crohn’s disease (К50), adults
Yu. A. Shelygin, В. Т. Ивашкин, С. И. Ачкасов, et al.
Koloproktologia (2023) Vol. 22, Iss. 3, pp. 10-49
Open Access | Times Cited: 23
The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story
Maria Skoufou, Christina Tsigalou, Stergios Vradelis, et al.
Microorganisms (2024) Vol. 12, Iss. 1, pp. 194-194
Open Access | Times Cited: 14
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 611-611
Open Access | Times Cited: 13
Methanogenic Archaea in the Pediatric Inflammatory Bowel Disease in Relation to Disease Type and Activity
Agata Anna Cisek, Edyta Szymańska, Aldona Wierzbicka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 673-673
Open Access | Times Cited: 8
Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU
Lucía Madero-Velázquez, Alejandro Mínguez, L Mayorga, et al.
United European Gastroenterology Journal (2025)
Open Access | Times Cited: 1
Gut microbiota in the early stage of Crohn’s disease has unique characteristics
Xianzong Ma, Xiaojuan Lu, Wenyu Zhang, et al.
Gut Pathogens (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 31
Periodontitis prevalence and severity in inflammatory bowel disease: A case–control study
Giacomo Baima, Mamdouh Muwalla, Giulia Testa, et al.
Journal of Periodontology (2022) Vol. 94, Iss. 3, pp. 313-322
Open Access | Times Cited: 29
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
Eleanor Liu, Nasar Aslam, Gaurav Nigam, et al.
Drugs in Context (2022) Vol. 11, pp. 1-17
Open Access | Times Cited: 28
Vaccines in Children Exposed to Biological AgentsIn Uteroand/or During Breastfeeding: Are They Effective and Safe?
Javier P. Gisbert, María Chaparro
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 6, pp. 995-1009
Closed Access | Times Cited: 17
Management of inflammatory bowel disease in the elderly: A review
Paula Sousa, Lorenzo Bertani, Cláudio Rodrigues
Digestive and Liver Disease (2023) Vol. 55, Iss. 8, pp. 1001-1009
Open Access | Times Cited: 17
Macrophage Tim-3 maintains intestinal homeostasis in DSS-induced colitis by suppressing neutrophil necroptosis
Fangfei Wang, Feng Zhou, Jianxiang Peng, et al.
Redox Biology (2024) Vol. 70, pp. 103072-103072
Open Access | Times Cited: 7
Antibiotics for inflammatory bowel disease: Current status
Daya Krishna Jha, Shubhra Mishra, Usha Dutta, et al.
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 145-159
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top